FDA published today that it will not hold an advisory committee meeting on ceftobiprole

FDA published today that it will not hold an advisory committee meeting on ceftobiprole

Basel, Switzerland, February 13, 2008

Basilea Pharmaceutica announces that the US Food and Drug Administration (FDA) determined that the Anti-Infective Drugs Advisory Committee meeting scheduled for February 28, 2008 will not be held, as provided for under the provisions of the amendment of Section 505 of the Federal Food, Drug, and Cosmetic Act.
Further information can be found in the Federal Register at: http://www.accessdata.fda.gov/scripts/oc/ohrms/advdisplay.cfm
and
http://www.fda.gov/ohrms/dockets/ac/cder08.html#AntiInfective


About Basilea
Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX: BSLN). The company focuses on the discovery, development and commercialization of innovative medicines for resistant bacterial infections, systemic fungal infections, and severe skin diseases.


Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.